Topical BRAF inhibitor LUT014 gel significantly reduces acneiform rash from anti-EGFR therapies in patients with colorectal ...

The role of EGFR in KRASG12D-driven tumorigenesis was studied using mouse CRC organoids with KRAS-APC-TP53 mutations and ...

C4 Therapeutics is sawing off another part of its solely owned pipeline, this time ending work on its clinical-stage BRAF ...

LUT014, a BRAF inhibitor gel, improved acne-like rashes in patients with colorectal cancer undergoing anti-EGFR therapy, ...

The molecular basis and mechanisms of action of combining classic cytotoxic agents (e.g. platinum-containing drugs, taxanes, etc.) and novel agents (e.g. tirapazamine, EGFR inhibitors and other ...

Novel treatment allowed patients with colorectal cancer to successfully continue taking their cancer treatment with improved quality of life. Acne-like skin rash is a common side effect from ...

The use of an investigational topical BRAF-inhibiting gel appeared to be effective in treating acneiform rash in patients ...

Announced focused registrational clinical development plans for lead programs, extended cash runway, and accelerated/augmented corporate milestones Presented preclinical data supporting potential best ...